Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations · 103.9M shares · +55%/yr ↑ dilution · EDGAR filings ↗
Reference price $5.00 · est. market cap ~$519M — last insider purchase, 2026-02-27 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — Friedreich's-ataxia biotech, heavy burn, funded.
Strengths
- Liquidity — current ratio 2.2 (28th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-113.3M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +55%/yr over 3y (dilution, book value/share -28%)
- Insider buyingInsider buying — 7 open-market buy(s) by 4 insider(s) (cluster of 4 insiders, ~$26M, last 6mo) Form 4 ↗
- Notable holderHeld by 5 notable fund(s): GOLDMAN SACHS GROUP INC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC +2 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2027-01 — PHASE2 · Friedreich Ataxia
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-212.2%
Return on assets
-113.6%
Current ratio
2.2×
Free cash flow
-$113M
Tangible book value
$78M
Cash & investments
$137M
Cash runway
5q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-27 | Flynn James E | Buy | 1.1M | $5.00 |
| 2026-02-27 | Flynn James E | Buy | 1.1M | $5.00 |
| 2026-02-27 | Flynn James E | Buy | 832K | $5.00 |
| 2026-02-27 | Flynn James E | Buy | 2.0M | $5.00 |
| 2026-02-27 | Hamilton Thomas Edward | Buy | 100K | $5.00 |
| 2026-02-27 | THOMAS FRANK E | Buy | 5.0K | $5.00 |
| 2026-02-27 | SHERMAN JEFFREY W | Buy | 5.0K | $5.00 |
| 2026-01-26 | Shankar Gopi | Grant | 26K | — |
| 2026-01-26 | Clayton Russell | Grant | 26K | — |
| 2026-01-26 | BEN-MAIMON CAROLE | Grant | 100K | — |
| 2026-01-26 | Celano Michael | Grant | 38K | — |
| 2025-07-31 | Flynn James E | Buy | 3.4M | $3.20 |
| 2025-07-31 | Flynn James E | Buy | 3.4M | $3.20 |
| 2025-07-31 | Flynn James E | Buy | 2.6M | $3.20 |
| 2025-01-22 | Shankar Gopi | Grant | 23K | — |
| 2025-01-22 | Clayton Russell | Grant | 23K | — |
| 2025-01-22 | BEN-MAIMON CAROLE | Grant | 91K | — |
| 2025-01-22 | Celano Michael | Grant | 34K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06447025 ↗ | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia Friedreich Ataxia | PHASE2 | Recruiting | 2027-01-01 |
| NCT06681766 ↗ | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia Friedreich Ataxia | PHASE1 | Terminated | 2025-04-28 |
| NCT05579691 ↗ | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia Friedreich Ataxia | PHASE2 | Completed | 2023-12-04 |
| NCT05028764 ↗ | Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers Friedreich Ataxia, Healthy Volunteers | — | Completed | 2022-02-04 |
| NCT04519567 ↗ | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia Friedreich Ataxia | PHASE1 | Completed | 2021-03-16 |
| NCT04176991 ↗ | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia Friedreich Ataxia | PHASE1 | Completed | 2020-10-31 |
| NCT04255680 ↗ | A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia Friedreich Ataxia | — | Completed | 2020-06-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-19 | 2026-05-19 | 0001193125-26-230852 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001193125-26-224087 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001193125-26-222746 ↗ |
| 10-K | 2026-03-19 | 2025-12-31 | 0001193125-26-115878 ↗ |
| 8-K | 2026-03-19 | 2026-03-19 | 0001193125-26-115119 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001193125-26-098493 ↗ |
| 8-K | 2026-02-27 | 2026-02-25 | 0001193125-26-077646 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001193125-26-065186 ↗ |
| 8-K | 2026-01-22 | 2026-01-21 | 0001193125-26-018664 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001193125-26-010409 ↗ |
| 8-K | 2025-12-17 | 2025-12-16 | 0001193125-25-321738 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001193125-25-273217 ↗ |